Comparison of Metformin, Flutamide and Simvastatin Effects on Metabolic complications of Polycystic Ovary Syndrome
Phase 3
- Conditions
- Polycystic Ovary Syndrome.polycystic Ovarian syndrome
- Registration Number
- IRCT201405217513N10
- Lead Sponsor
- Isfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 111
Inclusion Criteria
age = 18 years; being single; having no evidence for thyroid dysfunction, Cushing syndrome, and hyperprolactinaemia; to have normal kidney function, bilirubin level, and serum aminotransferases; none-smoker; not having breast cancer; not using any drug which probably affects the Ovarian function; insulin sensitivity and lipid profile; No contraindication to use drugs.
Exclusion criteria:
to refuse to continue the study; marriage; emerging side drugs effects or contraindication;
not to comply the study protocol.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Insulin resistance. Timepoint: baseline and after 6 month. Method of measurement: Homa-IR formula.;Fasting blood sugar. Timepoint: baseline and after 6 month. Method of measurement: mg/dl.;C-reactive protein. Timepoint: baseline and after 6 month. Method of measurement: mg/liter.;Blood pressure. Timepoint: baseline and after 6 month. Method of measurement: Blood pressure > 130/85 (mmHg).
- Secondary Outcome Measures
Name Time Method BMI. Timepoint: baseline - after 6 month. Method of measurement: weight (kg)/ height square (m).;Waist circumference. Timepoint: baseline - after 6 month. Method of measurement: cm.